1. Bray F, Ferlay J, Soerjomataram IS, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424.
Article
2. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res. 2010; 1:109–26.
3. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008; 359:2814–23.
Article
4. Roche J. The epithelial-to-mesenchymal transition in cancer. Cancers (Basel). 2018; 10:52.
Article
5. Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019; 79:1019–31.
Article
6. Yang ZY, Di MY, Yuan JQ, et al. The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Sci Rep. 2015; 5:7758.
Article
7. Riggio M, Perrone MC, Polo ML, et al. AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins. Sci Rep. 2017; 7:44244.
Article
8. Xu H, Tian Y, Yuan X, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther. 2015; 8:3783–92.
9. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2:177.
10. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12:207.
Article
11. O’Brien J, Hayder H, Peng C, et al. Automated quantification and analysis of cell counting procedures using ImageJ plugins. J Vis Exp. 2016; e54719.
Article
12. Choudhury KR, Yagle KJ, Swanson PE, Krohn KA, Rajendran JG. A robust automated measure of average antibody staining in immunohistochemistry images. J Histochem Cytochem. 2010; 58:95–107.
Article
13. Costa WH, Rocha RM, Cunha IW, Guimaraes GC, Zequi Sde C. Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance. Int Braz J Urol. 2012; 38:456–65.
Article
14. Sadeghi A, Roudi R, Mirzaei A, Zare Mirzaei A, Madjd Z, Abolhasani M. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer. Biomark Med. 2019; 13:419–26.
Article
15. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 2008; 50:419–30.
Article
16. Kallner A. Formulas. In : Kallner A, editor. Laboratory statistics: methods in chemistry and health sciences. 2nd ed. Cambridge: Elsevier;2018. p. 1–140.
17. Peng CY, Lee KL, Ingersoll GM. An introduction to logistic regression analysis and reporting. J Educ Res. 2002; 96:3–14.
Article
18. Wolf DM, Yau C, Wulfkuhle J, et al. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2020; 6:48.
Article
19. Toren W, Ansari D, Andersson R. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell Int. 2018; 18:217.
Article
20. Trigka EA, Levidou G, Saetta AA, et al. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep. 2013; 30:623–36.
Article
21. Malik SN, Brattain M, Ghosh PM, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res. 2002; 8:1168–71.
22. Koniali L, Hadjisavvas A, Constantinidou A, et al. Risk factors for breast cancer brain metastases: a systematic review. Oncotarget. 2020; 11:650–69.
Article
23. Hinz N, Jucker M. Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Signal. 2019; 17:154.
Article
24. Ye Y, Tang X, Sun Z, Chen S. Upregulated WDR26 serves as a scaffold to coordinate PI3K/AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget. 2016; 7:17854–69.
Article
25. Chen L, Fu H, Luo Y, et al. cPLA2alpha mediates TGF-beta-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling. Cell Death Dis. 2017; 8:e2728.
26. Kariri YA, Aleskandarany MA, Joseph C, et al. Molecular complexity of lymphovascular invasion: the role of cell migration in breast cancer as a prototype. Pathobiology. 2020; 87:218–31.
Article
27. Ribelles N, Santonja A, Pajares B, Llacer C, Alba E. The seed and soil hypothesis revisited: current state of knowledge of inherited genes on prognosis in breast cancer. Cancer Treat Rev. 2014; 40:293–9.
Article
28. Melzer C, von der Ohe J, Hass R. Breast carcinoma: from initial tumor cell detachment to settlement at secondary sites. Biomed Res Int. 2017; 2017:8534371.
Article
29. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg Oncol. 2004; 240:306–12.
Article
30. Nathanson SD, Kwon D, Kapke A, Alford SH, Chitale D. The role of lymph node metastasis in the systemic dissemination of breast cancer. Ann Surg Oncol. 2009; 16:3396–405.
Article
31. Wang Y, Dang X, Zhang M, Wei C, Li X. The role and correlation analysis of PI3K/AKT pathway in breast carcinoma with lymph node metastasis. J Immunopathol. 2018; 1:4–7.
32. Zhang S, Zhang D, Yi S, et al. The relationship of lymphatic vessel density, lymphovascular invasion, and lymph node metastasis in breast cancer: a systematic review and meta-analysis. Oncotarget. 2017; 8:2863–73.
Article
33. Pierceall WE, Wolfe M, Suschak J, et al. Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic response diagnostics. Anal Cell Pathol (Amst). 2011; 34:159–68.